Ref. No.

: WOCK/SEC/SE/2024-25/034 9th August, 2024

BSE Limited National Stock Exchange of India Limited

Corporate Relations Department Exchange Plaza
P J Towers Bandra Kurla Complex
Dalal Street Bandra (E)
Mumbai - 400 001 Mumbai - 400 051

Scrip Code: 532300 NSE Symbol: WOCKPHARMA

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting

Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015 ('Listing Regulations’); and in continuation to our letter bearing reference no.
Ref. No.: WOCK/SEC/SE/2024-25/032 dated 5th August, 2024, we wish to inform you that the
Board of Directors of the Company, at its meeting held today i.e.9th August, 2024, inter-alia, have
approved:

1. The Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June,
2024. Pursuant to Regulations 30 and 33 of Listing Regulations read with Para A of Part A of
Schedule III of Listing Regulations, we enclose herewith the Unaudited Financial Results
(Standalone & Consolidated) for the quarter ended 30th June, 2024 along with the Limited
Review Report thereon issued by M/s. M S K C & Associates., Statutory Auditors of the
Company as Annexure I.

2. Appointment of Mr. Paresh Kajrolkar, Head of Internal Audit, based on recommendations of

Audit Committee, as Internal Auditor of the Company w.e.f. 9th August, 2024.

The details required to be furnished pursuant under Regulation 30 of the Listing Regulations
read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
are enclosed herewith as Annexure-II.

The meeting of the Board of Directors commenced at 12:20 p.m. and concluded at 2:50 p.m.

Kindly take the same on record.

Thanking you,

For Wockhardt Limited

Rashmi Digitally signed
by Rashmi Dinesh
Dinesh Mamtura
Date: 2024.08.09
Mamtura 15:01:38 +05'30'

Rashmi Mamtura
Company Secretary

Encl: a/a
 602, Floor 6, Raheja Titanium
MSKC & Associates Western Express Highway. Geetanjali Railway Colony
Ram Nagar, Goregaon (E) Mumbai 400063, INDIA
Chartered Accountants

Independent Auditor’s Review Report on Standalone unaudited financial results of Wockhardt Limited
for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Wockhardt
Limited (hereinafter referred to as ‘the Company’) for the quarter ended June 30, 2024 (‘the
Statement’) attached herewith, being submitted by the Company pursuant to the requirements of
Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended (‘the Regulations’).

2. This Statement, which is the responsibility of the Company’s Management and has been approved by
the Company’s Board of Directors, has been prepared in accordance with the recognition and
measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’,
prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued
thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is
in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement
based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements
(SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the
Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial
information consists of making inquiries, primarily of persons responsible for financial and accounting
matters, and applying analytical and other review procedures. A review is substantially less in scope
than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of
the Act and consequently does not enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit. Accordingly, we do not express an audit
opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that
causes us to believe that the accompanying Statement prepared in accordance with the recognition and
measurement principles laid down in Ind AS 34 and other recognised accounting principles generally
accepted in India has not disclosed the information required to be disclosed in terms of the
Regulations, including the manner in which it is to be disclosed, or that it contains any material
misstatement.

Head Office: II Floor, 101-106 Congress Buildings, 573 Mount Road, Chennai, Tamil Nadu, India 600006
Tel: +91 44 2434 9866, +91 44 2434 9867
Bengaluru | Chennai | Mumbai
MSKC & Associates
Chartered Accountants

5. The comparative financial results of the Company for the quarter ended June 30, 2023 and for the year
ended March 31, 2024 included in this Statement had been reviewed/audited by the predecessor auditor
whose report dated August 14, 2023 and May 28, 2024 respectively, expressed an unmodified opinion on
that Statement.
Our conclusion is not modified in respect of the above matter.

For M S K C & Associates

Chartered Accountants
ICAI Firm Registration Number: 001595S

Place: Mumbai
Date: August 09, 2024

Head Office: II Floor, 101-106 Congress Buildings, 573 Mount Road, Chennai, Tamil Nadu, India 600006
Tel: +91 44 2434 9866, +91 44 2434 9867
Bengaluru | Chennai | Gurugram | Hyderabad | Mumbai
 WOCKHARDT LIMITED
Registered Office: D-4 MIDC, Chikallhana, Aurangabad - 431 006
Global Headquarters: Wockhardl Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
C1N:L24230MH 1999PLC120720
Tel: 91 22 2653 4444 ; Pax: 91 22 2652 3905; e-mail id : investorrelations(«;wockhardt com; Website: www.wockliardl.com

. ____________________________ (R * in ( 'i nre exce

STATEMENT OKSTANDALONK UNAUDITED RESULTS 1 OK THE QUARTER ENDED JUNE 30. 21124

PARTICULARS 3 MONTHS 3 MONTHS 3 MONTHS YEAR

ENDED ENDED ENDED ENDED
30/06/2024 31/03/2024 30/06/2023 31/03/2024

(Refer notes below) Unaudited Audited Unaudited Audited

(Refer note 2)
Incom e
1
(a) Revenue fiom opeiations 352 355 251 1,154
(b) Ollier: income 27 24 6 41
Total income 379 379 257 1,195
2 Expenses
(a) Cost of materials consumed 82 92 62 285
(b) Purchase o f stock-in-trade 31 41 35 162
(c) Changes in inventories of finished goods, work-in-progress and
stock-in-trade 14 2 6 14
(d) Employee benefits expense 62 62 63 247
(e) Finance costs 58 59 58 237
(f) Depreciation and amortisation expense 43 45 44 176
(g) Impairment of asset held for sale 79 79
(h) Exchange fluctuation loss, net 1
(i) Other expenses 82 125 90 403
Total expenses 373 505 358 1.603
3 P rollt/(Loss) before exceptional items and tax (1-2) 6 (126) (101) (408)
4 Exceptional items- charge (14) (14)
5 Profit/(Loss) after exceptional items before tax (3 ± 4) 6 (126) (115) (422)
6 Tax expense:
Current tax
Deferred tax - .
7 Net profit/(loss) after tax ( 5 ± 6) 6 (126) (115) (422)
X Other Comprehensive Income:
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (0.26) (3) 1 0)
(consisting of re-measurement o f net defined benefit (liabilily)/assel)

ii) Income tax relating to items that will not be reclassified to Profit or - -
Loss
iii) Other Comprehensive Income (net o f tax) (8i ± 8ii) (0.26) (3) I (1)
9 Total Com prehensive Incom e (7 ± 8(iii)) 6 (129) (114) (423)
10 Paid-up equity share capital (face value of Rs 5/- each) 77 77 72 77
11 Other Equity excluding Revaluation Reserves as per balance sheet 1,719
12 Earnings per share (face value o f Rs. 5/- each)
(*not annualised)
(a) Basic (Rs.) 0.39* (8.71)* (8.01)* (29.27)
(b) Diluted (Rs.) 0.39* (8.71)* (8.01)* (29.27)
 :2:

Nolo To Standalone Results

]) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 09, 2024. The results have been subjected to limited
review by the Statutory Auditors of the Company,

2) Figures for the quarter ended March 31, 2024 is the balancing figure between the audited figures of the full financial year and the reviewed figures uplo the third quarter of
financial year 2023-24.

3) The Company is exclusively into Pharmaceutical business Segment.

 602, Floor 6, Raheja Titanium
MSKC 6t Associates Western Express Highway, Geetanjali Railway Colony
Ram Nagar, Goregaon (E) Mumbai 400063, INDIA
Chartered Accountants

Independent Auditor’s Review Report on Consolidated unaudited financial results of Wockhardt

Limited for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of

Wockhardt Limited (hereinafter referred to as ‘the Holding Company’), its subsidiaries, (the Holding
Company and its subsidiaries together referred to as the ‘Group’) for the quarter ended June 30, 2024
(‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the
requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’).

2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the
Holding Company’s Board of Directors, has been prepared in accordance with the recognition and
measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’
prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued
thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in
compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based
on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements
(SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the
Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial
information consists of making inquiries, primarily of persons responsible for financial and accounting
matters, and applying analytical and other review procedures. A review is substantially less in scope
than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of
the Act and consequently does not enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit. Accordingly, we do not express an audit
opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange
Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No Name of the Entity Relationship with the Holding Company

1
Wockhardt UK Holdings Limited Wholly Owned Subsidiary

2 CP Pharmaceuticals Limited Step-Down Subsidiary

Head Office: II Floor, 101-106 Congress Buildings, 573 Mount Road, Chennai, Tamil Nadu, India 600006
Tel: +91 44 2434 9866, +91 44 7434 9867
Bengaluru | Chennai | Mumbai
MSKC & Associates
Chartered Accountants

3 CP Pharma (Schweiz) AG Step-Down Subsidiary

4 Wallis Group Limited Step-Down Subsidiary

5 The Wallis Laboratory Limited Step-Down Subsidiary

6 Wockhardt Farmaceutica Do Brasil Ltda Step-Down Subsidiary

7 Wallis Licensing Limited Step-Down Subsidiary

8 Wockhardt Infrastructure Development Wholly Owned Subsidiary

Limited

9 Z&Z Services GmbH Step-Down Subsidiary

10 Wockhardt Europe Limited Wholly Owned Subsidiary

11 Wockhardt Nigeria Limited Step-Down Subsidiary

12 Wockhardt USA LLC Step-Down Subsidiary

13 Wockhardt UK Limited Step-Down Subsidiary

14 Wockpharma Ireland Limited Step-Down Subsidiary

15 Pinewood Laboratories Limited Step-Down Subsidiary

16 Pinewood Healthcare Limited Step-Down Subsidiary

17 Wockhardt France (Holdings) S.A.S. Step-Down Subsidiary

18 Wockhardt Holding Corp. Step-Down Subsidiary

19 Morton Grove Pharmaceuticals Inc. Step-Down Subsidiary

20 MGP Inc. Step-Down Subsidiary

21 Wockhardt Farmaceutica SA DE CV Step-Down Subsidiary

22 Wockhardt Services SA DE CV Step-Down Subsidiary

23 Wockhardt Bio AG Subsidiary

24 Wockhardt Bio (R) LLC Step-Down Subsidiary

25 Wockhardt Bio Pty Limited Step-Down Subsidiary

26 Wockhardt Bio Limited Step-Down Subsidiary

27 Wockhardt Medicines Limited Wholly Owned Subsidiary

Head Office: II Floor, 101-106 Congress Buildings, 573 Mount Road, Chennai, Tamil Nadu, India 600006
Tel: +91 44 2434 9866, +91 44 2434 9867
Bengaluru | Chennai | Gurugram | Hyderabad | Mumbai
MSKC & Associates
Chartered Accountants

28 Wockhardt Bionova Limited (formerly known Wholly Owned Subsidiary

as Wockhardt Biologies Limited until April 22,
2024)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on
the consideration of the review reports of other auditors referred to in paragraph 6 and 7 below,
nothing has come to our attention that causes us to believe that the accompanying Statement prepared
in accordance with the recognition and measurement principles laid down in Ind AS 34 and other
recognised accounting principles generally accepted in India has not disclosed the information required
to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it
contains any material misstatement.

6. We did not review the interim financial information of 5 subsidiaries included in the Statement, whose
interim financial information (before Consolidation Adjustments) reflects total revenues of Rs. 660
crores, total net loss after tax of Rs. 20 crores and total comprehensive loss of Rs. 20 crores, for the
quarter ended June 30, 2024. These interim financial information have been reviewed by other auditors
whose reports have been furnished to us by the Management and our conclusion on the Statement, in so
far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely
on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.
Our conclusion is not modified in respect of the above matter with respect to our reliance on the work
done by and report of the other auditors.

7. The Statement includes the interim financial information of 17 subsidiaries which have not been
reviewed by their auditors, whose interim financial information (before Consolidation Adjustments)
reflects total revenue of Rs. 16 crores, total net profit after tax of Rs. 4 crores and total comprehensive
income of Rs. 4 crores for the quarter ended June 30, 2024. These interim financial information have
been furnished to us by the Management and our conclusion on the Statement in so far as it relates to
the amounts and disclosures included in respect of these subsidiaries is based solely on such
management prepared unaudited interim financial information. According to the information and
explanations given to us by the Management, these interim financial information are not material to the
Group.
Our conclusion is not modified in respect of the above matter with respect to our reliance on the
financial result certified by the management.

Head Office: II Floor, 101-106 Congress Buildings, 573 Mount Road, Chennai, Tamil Nadu, India 600006
Tel: +91 44 2434 9866, +91 44 2434 9867
Dengaluru | Chennai | Gurugram | Hyderabad | Mumbai
MSKC 8t Associates
Chartered Accountants

8. The comparative consolidated financial results of the Company for the quarter ended June 30, 2023 and
for the year ended March 31, 2024 included in this Statement had been reviewed/audited by the
predecessor auditor whose report dated August 14, 2023 and May 28, 2024 respectively, expressed an
unmodified opinion on that Statement.
Our conclusion is not modified in respect of the above matter.

For M S K C ft Associates
Chartered Accountants
ICAI Firm Registration Number: 001595S

Bhavik L. Shah
Membership No.: 122071
UDIN: 24122071BKENCW3723
Place: Mumbai
Date: August 09, 2024

Head Office: II Floor, 101-106 Congress Buildings, 573 Mount Road, Chennai, Tamil Nadu, India 600006
Tel: +91 44 2434 9866, +91 44 2434 9867
Bengaluru | Chennai | Gurugram | Hyderabad | Mumbai
 W OCKHARDT LIMITED
Registered O ffice: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: W ockhardt Tow ers, Bandra Kurla Complex, Bandra (East), Mumbai 4 00 051
CIN: L24230M H1999PLC120720
Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@ w ockhardt.com , W ebsite: w w w .w ockhardt.com

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

PARTICULARS 3 M O N TH S ENDED 3 M O N TH S ENDED 3 M O N TH S ENDED YEAR

30/06/2024 31/03/2024 30/06/2023 ENDED
31/03/2024

(Refer Notes Below) Unaudited Audited Unaudited Audited

(Refer note 4)
1 Income
(a) Revenue from operations 739 700 644 2,798
(b) Other income 30 54 14 83
Total income 769 754 658 2,881
2 Expenses
(a) Cost of m aterials consumed 150 144 137 620
(b) Purchase of stock-in-liade 153 154 150 559
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 10 (4) (5) (14)

(d) Employee benefits expense 160 157 154 629

(e) Finance costs 73 73 79 305
(f) Depreciation and am ortisation expense 54 58 55 223
(g) Impairment of asset held for sale 79 - 79
(h) Exchange fluctuation loss, net 1 - 2 -

(i) Loss on sale of property, plant and equipment - 44 52

(j) Other expenses 174 229 190 834
Total expenses 775 934 762 3,287
3 Loss before exceptional items and tax (1-2) (6) (180) (104) (406)
4 Exceptional items- charge (14) (14)
5 Loss afte r exceptional items and before tax (3 ± 4) (6) (180) (118) (420)
6 Tax expense:
Current tax - charge 2 2 9 16
Ueterreri tax - charge/ (credit) - (Net) 8 m . 9 36
7 Loss after tax (5 ± 6) (16) (177) (136) (472)
Attributable to :
Equity shareholders of the Company (14) (169) (134) (463)
Non Controlling Interest (2) (8) (2) (9)
8 Other fnm prehenjive Income
(u) Hums LlruL will nut b« rirclx.sklfleri to Profit or Lo t! (charge)/ a u d it (uunsistnig (t)./h ) (11) 1 m
of re-m easurem ent of net defined benefit (liability) / asset)

(b) Income tax relating to item s that will not be reclassified to Profit or Loss - r 1 1
eredlt/(charge)

(c) Items that w ill be reclassified to Profit nr 1nss - (charge)/ credit (Consisting of (3) (30) (2) 14
Exchange differences on translating the financial statem ents of foreign operations)

(d) Other Com prehensive Income (net of tax) (a ± b ± c) (3) (40) (1) 6

9 Total Comprehensive Incuine ( 7 1 8 (d|) (19) (21/) (137) (466)

Other Com prehensive Income attributable to
Equity shareholders of the Company (4) (36) 2
Non - Controlling Interest 1 (4) (1) 4
Total Com prehensive Income attributable to :
Equity shareholders of the Company (18) (205) (134) (461)
Non ■Controlling Interest (1) (12) (3) (5)
10 Paid-up equity share capital (face value of Ks. 5/- eauli) 77 77 u 77
11 Other Equity excluding Revaluation Reserves as per Balance, Sheet 3,282

12 Earnings per equity share (face value of Rs. 5/- each) ("n o t annualispd)
[a) Basic (Rs.) (0 .9 5)* (11.64)* (9.28)* (32.05)
|b) Diluted (Rs.) (0 .9 5)* (11.64)* (9.28)* (32.05)
Notes To C cm soli dated Results;-

1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 09; 2024. The results have been
subjected to limited review by the Statutory Auditors of the Company.

2) The Consolidated Results relate to Wockhardt Limited {'the Company1 or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are
prepared by applying Ind AS 110 - "Consolidated Financial Statements".

3) Key Financials on Standalone basis:

3 MONTHS 3 MONTHS 3 MONTHS

YEAR ENDED
PARTICULARS ENDED ENDED ENDED
31/03/2024
30/06/2024 31/03/2024 30/06/2023
Audited
Unaudited Unaudited Audited
(Refer Note 4)
Total Income 379 379 257 1.195
Profit (Loss) before tax 6 (126) (115) (422)
Profit (Loss) after tax 6 (126) 1115) (422)

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website
www.wockhardt.com.
4) Figures for the quarter ended March 31, 2024 is the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third
quarter of financial year 2023-24.

5} The Group is exclusively into Pharmaceutical business Segment.

6) For List of Subsidiaries as on June 30, 2024 please refer Annexure,

FOR WOCKHARDT LIMITED

CHAIRMAN
DIN:00045606
 WOCKHARDT LIMITED
Registered Office: D-4 MIDC, Chlkalthana, Aurangabad - 431006
Global Headquarters: WockhardtTowers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 6 of Consolidated unaudited Results for the Quarter ended June 30, 2024.

List of Subsidiaries as on June 30,2024

1 Wockhardt UK Holdings Limited

2 CP Pharmaceuticals Limited
3 CP Pharma (Schweiz) AG
4 Wallis Group Limited
5 The Wallis Laboratory Limited
6 Wockhardt Farmaceutica Do Brasil Ltda
7 Wallis Licensing Limited
8 Wockhardt Infrastructure Development Limited
9 Z & Z Services GmbH
10 Wockhardt Europe Limited
11 Wockhardt Nigeria I Imlteri
12 Wockhardt USA LLC
13 Wockhardt UK Limited
14 Wockpharma Ireland Limited
15 Plnewood Laboratories Limited
16 Plnewood Healthcare Limited
17 Wockhardt France (Holdings) S.A.S.
18 Wockhardt Holding Corp.
19 Morion Grove Phaunuceullcalt Inc.
20 MGP Inc.
21 Wockhardt Farmaceutica SA DE CV
22 Wockhardl Services SA DE CV
23 Wockhardt Bio AG
24 Wockhardt Bio (R) LLC
25 Wockhardt Bio Pty Limited
26 Wockhardt Bio Limited
27 Wockhardt Medicines Limited
28 Wockhardt Bionova Limited (formerly known as Wockhardt Biologies Limited untill April 22, 2024)
 Annexure II

The details required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI
Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr.no Particulars Details

1 Reason for change Appointment of Mr. Paresh Kajrolkar, Head of Internal Audit as
viz. appointment, re- Internal Auditor of the Company in place of Mr. Prasanna Bharatan,
appointment, who had resigned from the post of Internal Auditor from closing of
resignation, removal, business hours on Friday, 5th July, 2024.
death or otherwise

2 Date of Date of appointment: 9th August, 2024

appointment/re-
appointment/cessation Term of appointment: Mr. Kajrolkar will be employee of the Company
(as applicable) & term and his term will be governed as per applicable company policies.
of appointment/re-
appointment
3 Brief profile (in case of Mr. Paresh Kajrolkar has completed his Master of Management
appointment); Studies (silver medalist) with a specialization in System (IT) in 2005
from Mumbai University and BE (Electrical Engineering) from VJTI in
2000. He is also a Certified Fraud Examiner accredited by ACFE,
Texas, US (2017).

Mr. Kajrolkar has Approx. 22 years of work experience in Internal

audit, risk management, projects, procurement and cost saving.
Additionally he is skilled at fraud investigations and automation of
audit.

He has been associated with Wockhardt for the past 12 years as a

part of Internal Audits team reporting to the Chief Internal Auditor.
Prior to Wockhardt, he was working with Organizations viz. Mahajan
& Aibara, Volkswagen India Pvt. Ltd., Wockhardt, Macleods
Pharmaceuticals, etc.

4 Disclosure of Not Applicable

relationships between
directors (in case of
appointment of a
director).